Ensayo clínico para pacientes pediátricos con hipofosfatasia (HPP)

Hypophosphatasia is a rare, inherited metabolic disorder that affects the development of bones and teeth. This condition is caused by a deficiency of an enzyme called alkaline phosphatase, which leads to abnormalities in the mineralization of bones and teeth. The severity of symptoms can vary widely, ranging from mild forms that may not be diagnosed until adulthood to severe forms that can be life-threatening in infancy. Treatment for hypophosphatasia is focused on managing symptoms and may include medications to support bone health and dental care.

HPP se refiere a "High Pressure Processing", que en español se traduce como "Procesamiento de Alta Presión".

Asfotasa alfa es una enzima recombinante utilizada para el tratamiento de la hipofosfatasia, una enfermedad metabólica rara que afecta el metabolismo del fosfato y el calcio en el cuerpo. Esta enzima ayuda a restaurar los niveles normales de fosfato en el cuerpo y a fortalecer los huesos.

ALXN1850 is a code or reference number that does not have a specific translation. If you have more context or information about what ALXN1850 refers to, please provide it so that I can offer a more accurate translation.